Display options
Cite
Grimes DJ, Bowles MR, Buttsworth JA, et al. Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma. Drug Saf. 1990;5(6):447-54doi: 10.2165/00002018-199005060-00005.
Grimes, D. J., Bowles, M. R., Buttsworth, J. A., Thomson, D. B., Ravenscroft, P. J., Nixon, P. F., Whiting, R. F., & Pond, S. M. (1990). Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma. Drug safety, 5(6), 447-54. https://doi.org/10.2165/00002018-199005060-00005
Grimes, D J, et al. "Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma." Drug safety vol. 5,6 (1990): 447-54. doi: https://doi.org/10.2165/00002018-199005060-00005
Grimes DJ, Bowles MR, Buttsworth JA, Thomson DB, Ravenscroft PJ, Nixon PF, Whiting RF, Pond SM. Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma. Drug Saf. 1990 Nov-Dec;5(6):447-54. doi: 10.2165/00002018-199005060-00005. PMID: 2285498.
Copy Download .nbib Format: NLM
Share it on
Full text links
Springer

Drug Saf. 1990 Nov-Dec;5(6):447-54. doi: 10.2165/00002018-199005060-00005.

Survival after unexpected high serum methotrexate concentrations in a patient with osteogenic sarcoma.

Drug safety

D J Grimes, M R Bowles, J A Buttsworth, D B Thomson, P J Ravenscroft, P F Nixon, R F Whiting, S M Pond

Affiliations

  1. Division of Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

PMID: 2285498 DOI: 10.2165/00002018-199005060-00005

Abstract

An 18-year-old female patient receiving adjuvant chemotherapy for osteogenic sarcoma developed a pruritic erythematous rash during infusion of the eighth dose of methotrexate (8 g/m2) in the series. In other respects, the infusion proceeded normally but the 24-hour serum concentration of methotrexate was unexpectedly and extremely high, 574 mumols/L. Dosing error was excluded, as was the hypothesis that the high concentrations were due to the presence of methotrexate-specific antibodies. Acute oliguria and renal failure were the primary manifestations of the drug-induced toxicity and the high concentrations can be attributed to decreased renal elimination of the drug over the first 24 hours. Treatment consisted of folinic acid rescue, forced diuresis, sequential charcoal haemoperfusion and haemodialysis, and repeated oral doses of activated charcoal. After examination of the contribution of the extracorporeal procedures and the charcoal to the elimination of the drug, the relative lack of morbidity was attributed primarily to the folinic acid rescue and the intensive supportive care.

Similar articles

Cited by

References

  1. Immunochemistry. 1978 Jul;15(7):429-36 - PubMed
  2. Eur J Clin Pharmacol. 1980 Feb;17(2):123-7 - PubMed
  3. Cancer. 1969 Jan;23(1):126-31 - PubMed
  4. Cancer. 1980 Aug 1;46(3):471-4 - PubMed
  5. Cancer Treat Rep. 1977 Jul;61(4):745-8 - PubMed
  6. Clin Exp Pharmacol Physiol Suppl. 1979;5:35-41 - PubMed
  7. J Clin Oncol. 1983 Mar;1(3):208-16 - PubMed
  8. Clin Pharmacokinet. 1978 Jan-Feb;3(1):1-13 - PubMed
  9. Med Toxicol. 1986 Jan-Feb;1(1):3-11 - PubMed
  10. Cancer Chemother Pharmacol. 1981;6(1):59-64 - PubMed
  11. Cancer. 1982 Dec 15;50(12):2775-9 - PubMed
  12. Clin Exp Pharmacol Physiol. 1982 May-Jun;9(3):225-34 - PubMed
  13. Cancer Treat Rep. 1977 Aug;61(5):797-804 - PubMed
  14. Clin Exp Immunol. 1979 Jun;36(3):384-96 - PubMed
  15. J Cancer Res Clin Oncol. 1985;110(1):48-50 - PubMed
  16. Br Med J. 1978 Apr 29;1(6120):1097-9 - PubMed
  17. Cancer Treat Rep. 1982 May;66(5):1169-71 - PubMed
  18. Cancer Treat Rep. 1982 Sep;66(9):1733-41 - PubMed
  19. Am J Med. 1987 Feb;82(2):350-2 - PubMed
  20. Cancer. 1978 Jan;41(1):36-51 - PubMed
  21. Cancer. 1978 Jan;41(1):52-5 - PubMed
  22. Clin Pharmacol Ther. 1978 Mar;23(3):351-5 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources